products
ECI develops products to synergistically combine the tissue-repairing benefits of human platelet-rich plasma-derived growth factors and the sustained release action of hyaluronic acid or chitosan. This is done with the goal of providing both relief and long-lasting therapeutic effect.
treating neurotrophic keratitis (NK) and dry eye disease (DED)
ECI-102 and ECI-101 are ECI’s platelet-rich plasma-derived growth factor eye drops.
In early 2025, these products will jointly enter IND-enabling studies, focusing on neurotrophic keratitis (NK) and dry eye disease (DED) respectively.
ECI products leverage growth factors to help heal corneal damage. These biologically active proteins stimulate cell proliferation, repair damaged nerves, and restore the cornea’s structural and functional integrity, offering a targeted therapeutic approach for this challenging condition. Our advances in biologically derived growth factor formulations will help to address the unmet needs of persistent epithelial defect patients.
Neurotrophic keratitis is a rare degenerative corneal disease characterized by reduced or complete loss of corneal sensation, leading to impaired wound healing and corneal damage. It often arises from conditions such as herpes simplex or zoster infections, diabetes, or surgical damage to the trigeminal nerve. In severe cases, NK can lead to vision loss if left untreated. Growth factors play a critical role in treating NK by promoting nerve regeneration and corneal healing.
Dry eye disease is the most common ocular surface condition. There are 22 million dry eye patients in the United States, and of those, only 8 million are treated with only 25% reporting satisfaction with their treatment. There is a need for more effective treatments with fewer side effects.
pipeline
ECI is focused on developing products derived from platelet-rich human plasma-derived growth factors enhanced with hyaluronic acid or chitosan. From liquid eye drops to gels, ointments, and specially contoured bandages, our pipeline seeks to transform wound care, improve safety, and help heal the cornea, skin, burns, and more.
Eye care:
1. Persistent epithelial defects (NK, DED, chronic wounds)
2. Mucosal membrane dryness
3. ophthalmic burns.
Skin care:
1. Hard-to-heal wounds
2. Burns
3. Ulcers
Beyond:
Visit ECI’s pipeline page for more details.
learn more about:
our platform
Our platform leverages growth factors derived from donated human platelet-rich plasma and proprietary hyaluronic acid (HA) or chitosan. The tissue-repairing benefits of plasma-derived products, combined with the sustained action and impact of HA or chitosan, may provide relief and long-lasting therapeutic action.
our patients
Patients who experience conditions ranging from neurotrophic keratitis (NK) to dry eye disease (DED), wounds, or burns may benefit from our fusion of plasma and HA as a forward-thinking and potent strategy to potentially address their conditions with easier access and fewer side effects.
product safety
The safety of our products is paramount. To ensure that our products are as safe as possible, pathogen inactivation and removal technologies like the INTERCEPT Blood System for Plasma and nanofiltration have been incorporated into our manufacturing process.
ECI has met with the FDA and aligned on an orthogonal (multi-step) safety plan meeting all regulatory requirements.